文献速递外周血管儿科影像泌尿生殖MR

动态对比增强MR淋巴管成像:慢性肾病患者使用非罗莫司醇的可行性研究

Dynamic contrast-enhanced MR lymphangiography: feasibility of using ferumoxytol in patients with chronic kidney disease.
PubMed 文献 · Eur Radiol · 2022-01-10

该研究评估经淋巴管内直接注射稀释非罗莫司醇作为T1阳性对比剂,对患肾病儿童进行动态对比增强MR淋巴管成像(DCMRL)中央淋巴系统成像的可行性。体外扫描确定0.25至0.40 mg/mL非罗莫司醇在短TE(1至1.5 ms)3D GRE序列中保持高信号;4例肾病患儿经肠系膜内、肝内和淋巴结内途径注射稀释非罗莫司醇(每部位6至9 mL,平均总剂量0.75 mg/kg)后DCMRL均技术成功,淋巴管信噪比显著高于肌肉(50.1 ± 12.2 vs 13.2 ± 2.8;t = 15.9;p < .001),4例患者均无归因于非罗莫司醇给药的短期并发症。作者结论认为该方法是直接显示中央淋巴系统的新方法,基于4例初步报告可安全应用于肾衰竭患者。

要点

  • 稀释非罗莫司醇(0.25至0.40 mg/mL)在短TE(1至1.5 ms)3D GRE序列中保持高信号,可用于T1阳性淋巴管成像。
  • 经肠系膜内、肝内和淋巴结内途径注射稀释非罗莫司醇行DCMRL在4例肾病患儿中均技术成功,淋巴管信噪比显著高于肌肉(50.1 ± 12.2 vs 13.2 ± 2.8;p < .001)。
  • 4例患者均无归因于非罗莫司醇给药的短期并发症,作者基于此初步报告认为该方法可安全应用于肾衰竭患者。

核心结论

  • 经淋巴结内、肝内和肠系膜内途径使用非罗莫司醇的MR淋巴管成像是一种直接显示中央淋巴系统的新方法,基于4例初步报告可安全应用于肾衰竭患者。

研究设计与样本

  • 可行性研究;先进行稀释非罗莫司醇体外扫描(时间分辨和高分辨率3D GRE序列,短TE值1至1.5 ms),随后对4例肾病患儿行DCMRL,经肠系膜内、肝内和淋巴结内途径缓慢手动注射稀释非罗莫司醇(每部位6至9 mL;平均总剂量0.75 mg/kg;注射速度0.5至1.0 mL/min),测量淋巴管信噪比进行定量评估。

关键影像表现/征象

  • 非罗莫司醇浓度0.25至0.40 mg/mL在T1加权序列中保持高信号。
  • 淋巴管内对比剂显影充分,无需减影。
  • 淋巴管平均信噪比显著高于肌肉(50.1 ± 12.2 vs 13.2 ± 2.8;t = 15.9;p < .001)。

诊断标准与关键数值

  • 非罗莫司醇浓度0.25至0.40 mg/mL在短TE(1至1.5 ms)3D GRE序列中保持高信号。
  • DCMRL使用3D GRE序列,短TE值1至1.5 ms。
  • 注射参数:每部位6至9 mL,平均总剂量0.75 mg/kg,手动缓慢注射速度0.5至1.0 mL/min。

临床应用与阅片要点

  • 经肠系膜内、肝内和淋巴结内途径注射稀释非罗莫司醇可行DCMRL,直接显示从腹股沟至静脉角的中央淋巴系统。
  • 使用短TE(1至1.5 ms)3D GRE序列和适当稀释的非罗莫司醇(0.25至0.40 mg/mL)可获得诊断图像质量。
  • 作者基于4例初步报告认为该方法可安全应用于肾衰竭患者,4例均无归因于非罗莫司醇给药的短期并发症。

局限性

  • 作者结论基于4例初步报告,样本量小。
  • 作者称其为新方法,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the feasibility of direct intra-lymphatic administration of diluted ferumoxytol as a T1-positive contrast agent for dynamic contrast-enhanced MR lymphangiography (DCMRL) imaging of the central lymphatics in children with renal disease.

METHODS: In vitro scan of dilute ferumoxytol was initially performed using time-resolved and high-resolution 3D gradient echo (GRE) sequences with short TE values (1 to 1.5 ms). A ferumoxytol concentration of 0.25 to 0.40 mg/mL was found to retain high signal in the T1-weighted sequences. DCMRL was then performed in 4 children with renal disease with the same 3D GRE sequences administrating diluted ferumoxytol via intra-mesenteric (IM), intra-hepatic (IH), and intra-nodal (IN) routes (6 to 9 mL to each site; average total dose of 0.75 mg/kg) by slow hand injection (0.5 to 1.0 mL/min). The signal-to-noise ratio (SNR) of the lymphatics was measured for quantitative evaluation.

RESULTS: Ferumoxytol-enhanced DCMRL was technically successful in all patients. Contrast conspicuity within the lymphatics was sufficient without subtraction. The mean SNR was significantly higher than the muscle (50.1 ± 12.2 vs 13.2 ± 2.8; t = 15.9; p < .001). There were no short-term complications attributed to the administration of ferumoxytol in any of the four patients.

CONCLUSION: Magnetic resonance lymphangiography using ferumoxytol via IN, IH, and IM access is a new method to directly visualize the central lymphatic system and can be applied safely in patients with renal failure based on our preliminary report of four cases. Ferumoxytol-enhanced DCMRL shows diagnostic image quality by using 3D GRE sequences with short TE values and appropriate dilution of ferumoxytol.

KEY POINTS: • MR lymphangiography using ferumoxytol via intra-nodal, intra-hepatic, and intra-mesenteric access is a new method to directly visualize the central lymphatic system from the groin to the venous angle. • FDCMRL can be applied safely in patients with renal failure based on our preliminary report of four cases. • FDCMRL shows diagnostic image quality by using 3D GRE sequences with short TE values and appropriate dilution of the ferumoxytol.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Yekeler, Krishnamurthy, Smith, et al. Dynamic contrast-enhanced MR lymphangiography: feasibility of using ferumoxytol in patients with chronic kidney disease. Eur Radiol. 2022. PMID: 35001156. doi:10.1007/s00330-021-08448-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。